Chronic Administration of Anticholinergics in Rats Induces a Shift from Muscarinic to Purinergic Transmission in the Bladder Wall

Abstract Background First-line pharmacotherapy for overactive bladder consists of anticholinergics. However, patient compliance is exceptionally low, which may be due to progressive loss of effectiveness. Objective To decipher the involved molecular mechanisms and to evaluate the effects of chronic...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European urology 2013-09, Vol.64 (3), p.502-510
Hauptverfasser: Uvin, Pieter, Boudes, Mathieu, Menigoz, Aurélie, Franken, Jan, Pinto, Sílvia, Gevaert, Thomas, Verplaetse, Ruth, Tytgat, Jan, Vennekens, Rudi, Voets, Thomas, De Ridder, Dirk
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 510
container_issue 3
container_start_page 502
container_title European urology
container_volume 64
creator Uvin, Pieter
Boudes, Mathieu
Menigoz, Aurélie
Franken, Jan
Pinto, Sílvia
Gevaert, Thomas
Verplaetse, Ruth
Tytgat, Jan
Vennekens, Rudi
Voets, Thomas
De Ridder, Dirk
description Abstract Background First-line pharmacotherapy for overactive bladder consists of anticholinergics. However, patient compliance is exceptionally low, which may be due to progressive loss of effectiveness. Objective To decipher the involved molecular mechanisms and to evaluate the effects of chronic systemic administration of anticholinergics on bladder function and on muscarinic and purinergic receptors expression in rats. Design, setting, and participants Female Wistar rats were implanted with an osmotic pump that chronically administered vehicle (Vehc ), 0.36 mg/kg per day oxybutynin (Oxyc ), or 0.19 mg/kg per day fesoterodine (Fesoc ) for 28 d. Interventions For cystometry experiments, a small catheter was implanted in the bladder. Outcome measurements and statistical analysis Urologic phenotype was evaluated by the analysis of the micturition pattern and urodynamics. Expression of muscarinic and purinergic receptors was assessed by Western blot analysis of detrusor membrane protein. Functional responses to carbachol and adenosine triphosphate (ATP) were evaluated using muscle-strip contractility experiments. Results and limitations The number of voided spots was transiently decreased in Oxyc rats. In Oxyc rats, the effect of an acute high dose of oxybutynin (1 mg/kg intraperitoneally [IP]) on the intermicturition interval was abolished. Expression experiments revealed a decrease of muscarinic acetylcholine receptors M2 (mAChR2) and M3 (mAChR3), whereas the purinergic receptor P2X, ligand-gated ion channel, 1 (P2X1) was enhanced in Oxyc and Fesoc rats compared to Vehc rats. In concordance with the modification of the expression pattern in Oxyc rats, the force generated by carbachol and ATP in muscle-strip contractility experiments was, respectively, lower and higher. Urodynamics revealed that the effects of systemic administration of the purinergic blocker pyridoxalphosphate-6-azophenyl-2’,4’-disulphonic acid (50 mg/kg IP) were enhanced in Oxyc rats. As rat bladder physiology is different from that of humans, it is difficult to directly extrapolate our findings to human patients. Conclusions Chronic administration of anticholinergics in rats induces receptor loss of efficiency and a shift from muscarinic to purinergic transmission.
doi_str_mv 10.1016/j.eururo.2013.05.031
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1418365690</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0302283813004971</els_id><sourcerecordid>1418365690</sourcerecordid><originalsourceid>FETCH-LOGICAL-c447t-e74a2fd6e11e701f734276952727fb004fed44213bb4293bc5ecacaeb57e32e03</originalsourceid><addsrcrecordid>eNqFks2KFDEUhYMoTjv6BiLZCG6qzF9VujdC2_gzMKI4Iy5DKnVjp00lM0lKmKVvbopuFdy4yuY7J5fvXoSeUtJSQvuXhxbmNKfYMkJ5S7qWcHoPreha8kZ2PbmPVoQT1rA1X5-hRzkfCCG82_CH6IxxSWkn2Ar93O1TDM7g7Ti54HJJurgYcLR4G4oz--hdgPTNmYxdwJ91yfgijLOBjDW-2jtbsE1xwh_mbHRyS1WJ-NOcTjF8nXTIk8t5qa0VZQ_4tdfjCAl_1d4_Rg-s9hmenN5z9OXtm-vd--by47uL3fayMULI0oAUmtmxB0pBEmolF0z2m45JJu1AiLAwCsEoHwbBNnwwHRhtNAydBM6A8HP04th7k-LtDLmoOpQB73WAOGdFBV3zvus3CyqOqEkx5wRW3SQ36XSnKFGLfHVQR_lqka9Ip6r8Gnt2-mEeJhj_hH7brsDzE6CrLG-rGePyX072kgq5cK-OHFQfPxwklY2DYGB0CUxRY3T_m-TfAuOX1Wj_He4gH-KcQnWtqMpMEXW1HMpyJ5RXkRtJ-S8Uxbr1</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1418365690</pqid></control><display><type>article</type><title>Chronic Administration of Anticholinergics in Rats Induces a Shift from Muscarinic to Purinergic Transmission in the Bladder Wall</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Uvin, Pieter ; Boudes, Mathieu ; Menigoz, Aurélie ; Franken, Jan ; Pinto, Sílvia ; Gevaert, Thomas ; Verplaetse, Ruth ; Tytgat, Jan ; Vennekens, Rudi ; Voets, Thomas ; De Ridder, Dirk</creator><creatorcontrib>Uvin, Pieter ; Boudes, Mathieu ; Menigoz, Aurélie ; Franken, Jan ; Pinto, Sílvia ; Gevaert, Thomas ; Verplaetse, Ruth ; Tytgat, Jan ; Vennekens, Rudi ; Voets, Thomas ; De Ridder, Dirk</creatorcontrib><description>Abstract Background First-line pharmacotherapy for overactive bladder consists of anticholinergics. However, patient compliance is exceptionally low, which may be due to progressive loss of effectiveness. Objective To decipher the involved molecular mechanisms and to evaluate the effects of chronic systemic administration of anticholinergics on bladder function and on muscarinic and purinergic receptors expression in rats. Design, setting, and participants Female Wistar rats were implanted with an osmotic pump that chronically administered vehicle (Vehc ), 0.36 mg/kg per day oxybutynin (Oxyc ), or 0.19 mg/kg per day fesoterodine (Fesoc ) for 28 d. Interventions For cystometry experiments, a small catheter was implanted in the bladder. Outcome measurements and statistical analysis Urologic phenotype was evaluated by the analysis of the micturition pattern and urodynamics. Expression of muscarinic and purinergic receptors was assessed by Western blot analysis of detrusor membrane protein. Functional responses to carbachol and adenosine triphosphate (ATP) were evaluated using muscle-strip contractility experiments. Results and limitations The number of voided spots was transiently decreased in Oxyc rats. In Oxyc rats, the effect of an acute high dose of oxybutynin (1 mg/kg intraperitoneally [IP]) on the intermicturition interval was abolished. Expression experiments revealed a decrease of muscarinic acetylcholine receptors M2 (mAChR2) and M3 (mAChR3), whereas the purinergic receptor P2X, ligand-gated ion channel, 1 (P2X1) was enhanced in Oxyc and Fesoc rats compared to Vehc rats. In concordance with the modification of the expression pattern in Oxyc rats, the force generated by carbachol and ATP in muscle-strip contractility experiments was, respectively, lower and higher. Urodynamics revealed that the effects of systemic administration of the purinergic blocker pyridoxalphosphate-6-azophenyl-2’,4’-disulphonic acid (50 mg/kg IP) were enhanced in Oxyc rats. As rat bladder physiology is different from that of humans, it is difficult to directly extrapolate our findings to human patients. Conclusions Chronic administration of anticholinergics in rats induces receptor loss of efficiency and a shift from muscarinic to purinergic transmission.</description><identifier>ISSN: 0302-2838</identifier><identifier>EISSN: 1873-7560</identifier><identifier>DOI: 10.1016/j.eururo.2013.05.031</identifier><identifier>PMID: 23711542</identifier><identifier>CODEN: EUURAV</identifier><language>eng</language><publisher>Kidlington: Elsevier B.V</publisher><subject>Animals ; Anticholinergics ; Antimuscarinics ; Benzhydryl Compounds - administration &amp; dosage ; Biological and medical sciences ; Cholinergic Agonists - pharmacology ; Cholinergic Antagonists - administration &amp; dosage ; Cholinergic Neurons - drug effects ; Cholinergic Neurons - metabolism ; Female ; Fesoterodine ; Infusion Pumps, Implantable ; Mandelic Acids - administration &amp; dosage ; Medical sciences ; Muscarinic receptor ; Muscle Contraction - drug effects ; Nephrology. Urinary tract diseases ; Oxybutynin ; Purinergic P2X Receptor Agonists - pharmacology ; Purinergic P2X Receptor Antagonists - pharmacology ; Purinergic receptor ; Purines - metabolism ; Rats ; Rats, Wistar ; Receptor, Muscarinic M2 - drug effects ; Receptor, Muscarinic M2 - metabolism ; Receptor, Muscarinic M3 - drug effects ; Receptor, Muscarinic M3 - metabolism ; Receptors, Muscarinic - drug effects ; Receptors, Muscarinic - metabolism ; Receptors, Purinergic P2X1 - drug effects ; Receptors, Purinergic P2X1 - metabolism ; Synaptic Transmission - drug effects ; Time Factors ; Urinary Bladder - innervation ; Urinary Catheterization ; Urination - drug effects ; Urodynamics - drug effects ; Urological Agents - administration &amp; dosage ; Urology</subject><ispartof>European urology, 2013-09, Vol.64 (3), p.502-510</ispartof><rights>European Association of Urology</rights><rights>2013 European Association of Urology</rights><rights>2014 INIST-CNRS</rights><rights>Copyright © 2013 European Association of Urology. Published by Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c447t-e74a2fd6e11e701f734276952727fb004fed44213bb4293bc5ecacaeb57e32e03</citedby><cites>FETCH-LOGICAL-c447t-e74a2fd6e11e701f734276952727fb004fed44213bb4293bc5ecacaeb57e32e03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.eururo.2013.05.031$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,778,782,3539,27907,27908,45978</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=27671472$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23711542$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Uvin, Pieter</creatorcontrib><creatorcontrib>Boudes, Mathieu</creatorcontrib><creatorcontrib>Menigoz, Aurélie</creatorcontrib><creatorcontrib>Franken, Jan</creatorcontrib><creatorcontrib>Pinto, Sílvia</creatorcontrib><creatorcontrib>Gevaert, Thomas</creatorcontrib><creatorcontrib>Verplaetse, Ruth</creatorcontrib><creatorcontrib>Tytgat, Jan</creatorcontrib><creatorcontrib>Vennekens, Rudi</creatorcontrib><creatorcontrib>Voets, Thomas</creatorcontrib><creatorcontrib>De Ridder, Dirk</creatorcontrib><title>Chronic Administration of Anticholinergics in Rats Induces a Shift from Muscarinic to Purinergic Transmission in the Bladder Wall</title><title>European urology</title><addtitle>Eur Urol</addtitle><description>Abstract Background First-line pharmacotherapy for overactive bladder consists of anticholinergics. However, patient compliance is exceptionally low, which may be due to progressive loss of effectiveness. Objective To decipher the involved molecular mechanisms and to evaluate the effects of chronic systemic administration of anticholinergics on bladder function and on muscarinic and purinergic receptors expression in rats. Design, setting, and participants Female Wistar rats were implanted with an osmotic pump that chronically administered vehicle (Vehc ), 0.36 mg/kg per day oxybutynin (Oxyc ), or 0.19 mg/kg per day fesoterodine (Fesoc ) for 28 d. Interventions For cystometry experiments, a small catheter was implanted in the bladder. Outcome measurements and statistical analysis Urologic phenotype was evaluated by the analysis of the micturition pattern and urodynamics. Expression of muscarinic and purinergic receptors was assessed by Western blot analysis of detrusor membrane protein. Functional responses to carbachol and adenosine triphosphate (ATP) were evaluated using muscle-strip contractility experiments. Results and limitations The number of voided spots was transiently decreased in Oxyc rats. In Oxyc rats, the effect of an acute high dose of oxybutynin (1 mg/kg intraperitoneally [IP]) on the intermicturition interval was abolished. Expression experiments revealed a decrease of muscarinic acetylcholine receptors M2 (mAChR2) and M3 (mAChR3), whereas the purinergic receptor P2X, ligand-gated ion channel, 1 (P2X1) was enhanced in Oxyc and Fesoc rats compared to Vehc rats. In concordance with the modification of the expression pattern in Oxyc rats, the force generated by carbachol and ATP in muscle-strip contractility experiments was, respectively, lower and higher. Urodynamics revealed that the effects of systemic administration of the purinergic blocker pyridoxalphosphate-6-azophenyl-2’,4’-disulphonic acid (50 mg/kg IP) were enhanced in Oxyc rats. As rat bladder physiology is different from that of humans, it is difficult to directly extrapolate our findings to human patients. Conclusions Chronic administration of anticholinergics in rats induces receptor loss of efficiency and a shift from muscarinic to purinergic transmission.</description><subject>Animals</subject><subject>Anticholinergics</subject><subject>Antimuscarinics</subject><subject>Benzhydryl Compounds - administration &amp; dosage</subject><subject>Biological and medical sciences</subject><subject>Cholinergic Agonists - pharmacology</subject><subject>Cholinergic Antagonists - administration &amp; dosage</subject><subject>Cholinergic Neurons - drug effects</subject><subject>Cholinergic Neurons - metabolism</subject><subject>Female</subject><subject>Fesoterodine</subject><subject>Infusion Pumps, Implantable</subject><subject>Mandelic Acids - administration &amp; dosage</subject><subject>Medical sciences</subject><subject>Muscarinic receptor</subject><subject>Muscle Contraction - drug effects</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Oxybutynin</subject><subject>Purinergic P2X Receptor Agonists - pharmacology</subject><subject>Purinergic P2X Receptor Antagonists - pharmacology</subject><subject>Purinergic receptor</subject><subject>Purines - metabolism</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Receptor, Muscarinic M2 - drug effects</subject><subject>Receptor, Muscarinic M2 - metabolism</subject><subject>Receptor, Muscarinic M3 - drug effects</subject><subject>Receptor, Muscarinic M3 - metabolism</subject><subject>Receptors, Muscarinic - drug effects</subject><subject>Receptors, Muscarinic - metabolism</subject><subject>Receptors, Purinergic P2X1 - drug effects</subject><subject>Receptors, Purinergic P2X1 - metabolism</subject><subject>Synaptic Transmission - drug effects</subject><subject>Time Factors</subject><subject>Urinary Bladder - innervation</subject><subject>Urinary Catheterization</subject><subject>Urination - drug effects</subject><subject>Urodynamics - drug effects</subject><subject>Urological Agents - administration &amp; dosage</subject><subject>Urology</subject><issn>0302-2838</issn><issn>1873-7560</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFks2KFDEUhYMoTjv6BiLZCG6qzF9VujdC2_gzMKI4Iy5DKnVjp00lM0lKmKVvbopuFdy4yuY7J5fvXoSeUtJSQvuXhxbmNKfYMkJ5S7qWcHoPreha8kZ2PbmPVoQT1rA1X5-hRzkfCCG82_CH6IxxSWkn2Ar93O1TDM7g7Ti54HJJurgYcLR4G4oz--hdgPTNmYxdwJ91yfgijLOBjDW-2jtbsE1xwh_mbHRyS1WJ-NOcTjF8nXTIk8t5qa0VZQ_4tdfjCAl_1d4_Rg-s9hmenN5z9OXtm-vd--by47uL3fayMULI0oAUmtmxB0pBEmolF0z2m45JJu1AiLAwCsEoHwbBNnwwHRhtNAydBM6A8HP04th7k-LtDLmoOpQB73WAOGdFBV3zvus3CyqOqEkx5wRW3SQ36XSnKFGLfHVQR_lqka9Ip6r8Gnt2-mEeJhj_hH7brsDzE6CrLG-rGePyX072kgq5cK-OHFQfPxwklY2DYGB0CUxRY3T_m-TfAuOX1Wj_He4gH-KcQnWtqMpMEXW1HMpyJ5RXkRtJ-S8Uxbr1</recordid><startdate>20130901</startdate><enddate>20130901</enddate><creator>Uvin, Pieter</creator><creator>Boudes, Mathieu</creator><creator>Menigoz, Aurélie</creator><creator>Franken, Jan</creator><creator>Pinto, Sílvia</creator><creator>Gevaert, Thomas</creator><creator>Verplaetse, Ruth</creator><creator>Tytgat, Jan</creator><creator>Vennekens, Rudi</creator><creator>Voets, Thomas</creator><creator>De Ridder, Dirk</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20130901</creationdate><title>Chronic Administration of Anticholinergics in Rats Induces a Shift from Muscarinic to Purinergic Transmission in the Bladder Wall</title><author>Uvin, Pieter ; Boudes, Mathieu ; Menigoz, Aurélie ; Franken, Jan ; Pinto, Sílvia ; Gevaert, Thomas ; Verplaetse, Ruth ; Tytgat, Jan ; Vennekens, Rudi ; Voets, Thomas ; De Ridder, Dirk</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c447t-e74a2fd6e11e701f734276952727fb004fed44213bb4293bc5ecacaeb57e32e03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Animals</topic><topic>Anticholinergics</topic><topic>Antimuscarinics</topic><topic>Benzhydryl Compounds - administration &amp; dosage</topic><topic>Biological and medical sciences</topic><topic>Cholinergic Agonists - pharmacology</topic><topic>Cholinergic Antagonists - administration &amp; dosage</topic><topic>Cholinergic Neurons - drug effects</topic><topic>Cholinergic Neurons - metabolism</topic><topic>Female</topic><topic>Fesoterodine</topic><topic>Infusion Pumps, Implantable</topic><topic>Mandelic Acids - administration &amp; dosage</topic><topic>Medical sciences</topic><topic>Muscarinic receptor</topic><topic>Muscle Contraction - drug effects</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Oxybutynin</topic><topic>Purinergic P2X Receptor Agonists - pharmacology</topic><topic>Purinergic P2X Receptor Antagonists - pharmacology</topic><topic>Purinergic receptor</topic><topic>Purines - metabolism</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Receptor, Muscarinic M2 - drug effects</topic><topic>Receptor, Muscarinic M2 - metabolism</topic><topic>Receptor, Muscarinic M3 - drug effects</topic><topic>Receptor, Muscarinic M3 - metabolism</topic><topic>Receptors, Muscarinic - drug effects</topic><topic>Receptors, Muscarinic - metabolism</topic><topic>Receptors, Purinergic P2X1 - drug effects</topic><topic>Receptors, Purinergic P2X1 - metabolism</topic><topic>Synaptic Transmission - drug effects</topic><topic>Time Factors</topic><topic>Urinary Bladder - innervation</topic><topic>Urinary Catheterization</topic><topic>Urination - drug effects</topic><topic>Urodynamics - drug effects</topic><topic>Urological Agents - administration &amp; dosage</topic><topic>Urology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Uvin, Pieter</creatorcontrib><creatorcontrib>Boudes, Mathieu</creatorcontrib><creatorcontrib>Menigoz, Aurélie</creatorcontrib><creatorcontrib>Franken, Jan</creatorcontrib><creatorcontrib>Pinto, Sílvia</creatorcontrib><creatorcontrib>Gevaert, Thomas</creatorcontrib><creatorcontrib>Verplaetse, Ruth</creatorcontrib><creatorcontrib>Tytgat, Jan</creatorcontrib><creatorcontrib>Vennekens, Rudi</creatorcontrib><creatorcontrib>Voets, Thomas</creatorcontrib><creatorcontrib>De Ridder, Dirk</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European urology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Uvin, Pieter</au><au>Boudes, Mathieu</au><au>Menigoz, Aurélie</au><au>Franken, Jan</au><au>Pinto, Sílvia</au><au>Gevaert, Thomas</au><au>Verplaetse, Ruth</au><au>Tytgat, Jan</au><au>Vennekens, Rudi</au><au>Voets, Thomas</au><au>De Ridder, Dirk</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Chronic Administration of Anticholinergics in Rats Induces a Shift from Muscarinic to Purinergic Transmission in the Bladder Wall</atitle><jtitle>European urology</jtitle><addtitle>Eur Urol</addtitle><date>2013-09-01</date><risdate>2013</risdate><volume>64</volume><issue>3</issue><spage>502</spage><epage>510</epage><pages>502-510</pages><issn>0302-2838</issn><eissn>1873-7560</eissn><coden>EUURAV</coden><abstract>Abstract Background First-line pharmacotherapy for overactive bladder consists of anticholinergics. However, patient compliance is exceptionally low, which may be due to progressive loss of effectiveness. Objective To decipher the involved molecular mechanisms and to evaluate the effects of chronic systemic administration of anticholinergics on bladder function and on muscarinic and purinergic receptors expression in rats. Design, setting, and participants Female Wistar rats were implanted with an osmotic pump that chronically administered vehicle (Vehc ), 0.36 mg/kg per day oxybutynin (Oxyc ), or 0.19 mg/kg per day fesoterodine (Fesoc ) for 28 d. Interventions For cystometry experiments, a small catheter was implanted in the bladder. Outcome measurements and statistical analysis Urologic phenotype was evaluated by the analysis of the micturition pattern and urodynamics. Expression of muscarinic and purinergic receptors was assessed by Western blot analysis of detrusor membrane protein. Functional responses to carbachol and adenosine triphosphate (ATP) were evaluated using muscle-strip contractility experiments. Results and limitations The number of voided spots was transiently decreased in Oxyc rats. In Oxyc rats, the effect of an acute high dose of oxybutynin (1 mg/kg intraperitoneally [IP]) on the intermicturition interval was abolished. Expression experiments revealed a decrease of muscarinic acetylcholine receptors M2 (mAChR2) and M3 (mAChR3), whereas the purinergic receptor P2X, ligand-gated ion channel, 1 (P2X1) was enhanced in Oxyc and Fesoc rats compared to Vehc rats. In concordance with the modification of the expression pattern in Oxyc rats, the force generated by carbachol and ATP in muscle-strip contractility experiments was, respectively, lower and higher. Urodynamics revealed that the effects of systemic administration of the purinergic blocker pyridoxalphosphate-6-azophenyl-2’,4’-disulphonic acid (50 mg/kg IP) were enhanced in Oxyc rats. As rat bladder physiology is different from that of humans, it is difficult to directly extrapolate our findings to human patients. Conclusions Chronic administration of anticholinergics in rats induces receptor loss of efficiency and a shift from muscarinic to purinergic transmission.</abstract><cop>Kidlington</cop><pub>Elsevier B.V</pub><pmid>23711542</pmid><doi>10.1016/j.eururo.2013.05.031</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0302-2838
ispartof European urology, 2013-09, Vol.64 (3), p.502-510
issn 0302-2838
1873-7560
language eng
recordid cdi_proquest_miscellaneous_1418365690
source MEDLINE; ScienceDirect Journals (5 years ago - present)
subjects Animals
Anticholinergics
Antimuscarinics
Benzhydryl Compounds - administration & dosage
Biological and medical sciences
Cholinergic Agonists - pharmacology
Cholinergic Antagonists - administration & dosage
Cholinergic Neurons - drug effects
Cholinergic Neurons - metabolism
Female
Fesoterodine
Infusion Pumps, Implantable
Mandelic Acids - administration & dosage
Medical sciences
Muscarinic receptor
Muscle Contraction - drug effects
Nephrology. Urinary tract diseases
Oxybutynin
Purinergic P2X Receptor Agonists - pharmacology
Purinergic P2X Receptor Antagonists - pharmacology
Purinergic receptor
Purines - metabolism
Rats
Rats, Wistar
Receptor, Muscarinic M2 - drug effects
Receptor, Muscarinic M2 - metabolism
Receptor, Muscarinic M3 - drug effects
Receptor, Muscarinic M3 - metabolism
Receptors, Muscarinic - drug effects
Receptors, Muscarinic - metabolism
Receptors, Purinergic P2X1 - drug effects
Receptors, Purinergic P2X1 - metabolism
Synaptic Transmission - drug effects
Time Factors
Urinary Bladder - innervation
Urinary Catheterization
Urination - drug effects
Urodynamics - drug effects
Urological Agents - administration & dosage
Urology
title Chronic Administration of Anticholinergics in Rats Induces a Shift from Muscarinic to Purinergic Transmission in the Bladder Wall
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T06%3A25%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Chronic%20Administration%20of%20Anticholinergics%20in%20Rats%20Induces%20a%20Shift%20from%20Muscarinic%20to%20Purinergic%20Transmission%20in%20the%20Bladder%20Wall&rft.jtitle=European%20urology&rft.au=Uvin,%20Pieter&rft.date=2013-09-01&rft.volume=64&rft.issue=3&rft.spage=502&rft.epage=510&rft.pages=502-510&rft.issn=0302-2838&rft.eissn=1873-7560&rft.coden=EUURAV&rft_id=info:doi/10.1016/j.eururo.2013.05.031&rft_dat=%3Cproquest_cross%3E1418365690%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1418365690&rft_id=info:pmid/23711542&rft_els_id=S0302283813004971&rfr_iscdi=true